Aurum Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 16-06-2024
- Paid Up Capital ₹ 1.15 M
as on 16-06-2024
- Company Age 26 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.79 Cr
as on 16-06-2024
- Satisfied Charges ₹ 7.38 Cr
as on 16-06-2024
- Revenue 78.88%
(FY 2023)
- Profit -49.26%
(FY 2023)
- Ebitda -30.62%
(FY 2023)
- Net Worth 1.47%
(FY 2023)
- Total Assets 30.18%
(FY 2023)
About Aurum Pharmachem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.15 M.
The company currently has active open charges totaling ₹4.79 Cr. The company has closed loans amounting to ₹7.38 Cr, as per Ministry of Corporate Affairs (MCA) records.
Moti Bhura, Ankit Bhura, Jai Bothra, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232WB1998PTC086880
- Company No.
086880
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Mar 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aurum Pharmachem Private Limited offer?
Aurum Pharmachem Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Speciality Chemicals.
Who are the key members and board of directors at Aurum Pharmachem?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirmal Bhura  | Director | 20-Jun-2007 | Current |
| Jai Bothra | Director | 30-Mar-1998 | Current |
| Ankit Bhura | Director | 02-Sep-2019 | Current |
| Moti Bhura | Director | 03-Oct-2005 | Current |
Financial Performance of Aurum Pharmachem.
Aurum Pharmachem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 78.88% increase. The company also saw a substantial fall in profitability, with a 49.26% decrease in profit. The company's net worth moved up by a moderate rise of 1.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aurum Pharmachem?
In 2023, Aurum Pharmachem had a promoter holding of 64.21% and a public holding of 35.79%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Aurum Chemicals Private LimitedActive 28 years 9 months
Jai Bothra and Nirmal Bhura are mutual person
- Panther Tie-Up Private LimitedActive 14 years 9 months
Jai Bothra and Nirmal Bhura are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Jul 2023 | ₹4.79 Cr | Open |
Others Creation Date: 27 Jul 2018 | ₹2.80 Cr | Satisfied |
The Royal Bank Of Scotland N. V. Creation Date: 01 Sep 2011 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Aurum Pharmachem?
Aurum Pharmachem has a workforce of 19 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aurum Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aurum Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
